Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A fekélyes vastagbélgyulladás gyógyszeres és sebészeti kezelése.
Miheller P, Kristóf T, Bor R, Farkas K, Golovics P, Harsányi L, Müller KE, Milassin Á, Palatka K, Schäfer E, Szamosi T, Sarlós P, Molnár T. Miheller P, et al. Among authors: palatka k. Orv Hetil. 2024 Mar 12;165(Supplement-1):37-64. doi: 10.1556/650.2024.33050. Print 2024 Mar 12. Orv Hetil. 2024. PMID: 38470491 Hungarian. No abstract available.
A Crohn-betegég terápiás stratégiája.
Farkas K, Székely H, Bacsur P, Bánky B, Élthes ZB, Harsányi L, Müllner KE, Milassin Á, Palatka K, Sarlós P, Szamosi T, Molnár T, Miheller P. Farkas K, et al. Among authors: palatka k. Orv Hetil. 2024 Mar 12;165(Supplement-1):1-36. doi: 10.1556/650.2024.33020. Print 2024 Mar 12. Orv Hetil. 2024. PMID: 38470481 Hungarian. No abstract available.
[Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary].
Kiss LS, Szamosi T, Molnár T, Miheller P, Lakatos L, Vincze A, Palatka K, Bartha Z, Gasztonyi B, Salamon A, Horváth G, Tóth GT, Farkas K, Banai J, Tulassay Z, Nagy F, Szenes M, Veres G, Lovász BD, Végh Z, Golovics PA, Szathmári M, Papp M, Lakatos PL. Kiss LS, et al. Among authors: palatka k. Orv Hetil. 2011 Sep 4;152(36):1433-42. doi: 10.1556/OH.2011.29200. Orv Hetil. 2011. PMID: 21865144 Hungarian.
[Hungarian data on inflammatory bowel diseases: analytical data on ulcerative colistis].
Miheller P, Nagy F, Palatka K, Altorjay I, Horváth G, Lőrinczy K, Újszászy L, Virányi Z, Szepes A, Molnár T, Farkas K, Szepes Z, Nyári T, Wittmann T, Tulassay Z. Miheller P, et al. Among authors: palatka k. Orv Hetil. 2012 May 6;153(18):702-12. doi: 10.1556/OH.2012.29361. Orv Hetil. 2012. PMID: 22547465 Hungarian.
[Long-term adalimumab therapy in ulcerative colitis in clinical practice: result of the Hungarian multicenter prospective study].
Rutka M, Bálint A, Farkas K, Palatka K, Lakner L, Miheller P, Rácz I, Hegede G, Vincze Á, Horváth G, Szabó A, Nagy F, Szepes Z, Gábor Z, Zsigmond F, Zsóri Á, Juhász M, Csontos Á, Szűcs M, Bor R, Milassin Á, Molnár T. Rutka M, et al. Among authors: palatka k. Orv Hetil. 2016 May 1;157(18):706-11. doi: 10.1556/650.2016.30429. Orv Hetil. 2016. PMID: 27106726 Clinical Trial. Hungarian.
[Treatment adherence and use of complementary and alternative medicine in patients with inflammatory bowel disease].
Lakatos L, Czeglédi Z, Dávid G, Kispál Z, Kiss LS, Palatka K, Kristóf T, Molnár T, Salamon A, Demeter P, Miheller P, Szamosi T, Banai J, Papp M, Bene L, Kovács A, Rácz I, Lakatos PL. Lakatos L, et al. Among authors: palatka k. Orv Hetil. 2010 Feb 14;151(7):250-8. doi: 10.1556/OH.2010.28805. Orv Hetil. 2010. PMID: 20133244 Hungarian.
Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease - A nationwide Hungarian cohort study.
Bor R, Fábián A, Matuz M, Szepes Z, Farkas K, Miheller P, Szamosi T, Vincze Á, Rutka M, Szántó K, Bálint A, Nagy F, Milassin Á, Tóth T, Zsigmond F, Bajor J, Müllner K, Lakner L, Papp M, Salamon Á, Horváth G, Sarang K, Schäfer E, Sarlós P, Palatka K, Molnár T. Bor R, et al. Among authors: palatka k. Expert Opin Biol Ther. 2020 Feb;20(2):205-213. doi: 10.1080/14712598.2020.1699529. Epub 2019 Dec 6. Expert Opin Biol Ther. 2020. PMID: 31782939
Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?
Gonczi L, Vegh Z, Golovics PA, Rutka M, Gecse KB, Bor R, Farkas K, Szamosi T, Bene L, Gasztonyi B, Kristóf T, Lakatos L, Miheller P, Palatka K, Papp M, Patai Á, Salamon Á, Tóth GT, Vincze Á, Biro E, Lovasz BD, Kurti Z, Szepes Z, Molnár T, Lakatos PL. Gonczi L, et al. Among authors: palatka k. J Crohns Colitis. 2017 Jun 1;11(6):697-705. doi: 10.1093/ecco-jcc/jjw203. J Crohns Colitis. 2017. PMID: 27838610
[Haptoglobin polymorphism in patients with inflammatory bowel diseases].
Papp M, Lakatos PL; Hungarian IBD Study Group; Palatka K, Földi I, Udvardy M, Hársfalvi J, Tornai I, Vitális Z, Dinya T, Kovács A, Molnár T, Demeter P, Papp J, Lakatos L, Altorjay I. Papp M, et al. Among authors: palatka k. Orv Hetil. 2006 Sep 10;147(36):1745-50. Orv Hetil. 2006. PMID: 17087019 Hungarian.
73 results